RecruitingRelapsed and/or Refractory Multiple Myeloma
A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma
Eligible age
18+ yrs
Accepts
All genders
Locations
9 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to assess BMS-986453 in participants with relapsed and/or refractory multiple myeloma (RRMM).
Sponsor: Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
You may qualify if…
- ✓ Participants must have a diagnosis of multiple myeloma with relapsed and/or refractory disease.
- ✓ Participants must have confirmed progressive disease on or within 12 months (measured from the last dose) of completing treatment with the last anti-myeloma treatment regimen before study entry.
- ✓ Participants in Part A and Part B Cohort 1 and in Part B Cohort 2 must have relapsed/refractory multiple myeloma and received previous antimyeloma therapy, including a proteasome inhibitor and an immunomodulatory agent.
- ✓ Participants must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- ✓ Participants must have adequate organ function.
You may not qualify if…
- ✕ Participants must not have any known active or history of central nervous system (CNS) involvement of multiple myeloma.
- ✕ Participants must not have active or history of plasma cell leukemia, Waldenstrom's macroglobulinemia, POEMS (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes) syndrome, or clinically significant amyloidosis.
- ✕ Participants must not have a history or presence of clinically significant CNS pathology such as seizure disorder, aphasia, stroke, severe brain injury, dementia, Parkinson's disease, or cerebellar disease, or presence of clinically active psychosis.
- ✕ Other protocol-defined inclusion/exclusion criteria apply.
Where it's recruiting
Alabama
Birmingham
California
Duarte · San Francisco · Stanford
Colorado
Denver
Connecticut
New Haven
Florida
Tampa
Massachusetts
Boston
New York
New York
Tennessee
Nashville
Washington
Seattle
Source: ClinicalTrials.gov · NCT06153251 · last updated 2026-03-18